Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Univ. of Münster cPLA2α compound 7
- Development stage
- Unknown
- Lead developer
- Universität Münster
01
Overview
Univ. of Münster cPLA2α compound 7: sourced facts only. name: "Recently, in a ligand-based virtual screening approach, 2,4-dichlorobenzyl-substituted 4-[2-(indol-3-ylmethylene)hydrazineyl]benzoic acid 7 was found to be an inhibitor of cPLA2α with micromolar activity." [PMID:38389890]; target: "Recently, in a ligand-based virtual screening approach, 2,4-dichlorobenzyl-substituted 4-[2-(indol-3-ylmethylene)hydrazineyl]benzoic acid 7 was found to be an inhibitor of cPLA2α with micromolar activity." [PMID:38389890]; developer: "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster Corrensstrasse 48 48149 Münster Germany [email protected]." [PMID:38389890]
02
Targets
PLA2G4A (Cytosolic phospholipase A2 alpha)
Beyond the preview
Go deeper on Univ. of Münster cPLA2α compound 7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Univ. of Münster cPLA2α compound 7.